These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 36551617)

  • 1. Cancer Immunotherapy: The Checkpoint between Chronic Colitis and Colorectal Cancer.
    Ephraim R; Feehan J; Fraser S; Nurgali K; Apostolopoulos V
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Gene Expression of Checkpoint Markers and Cancer Markers in Mouse Models of Spontaneous Chronic Colitis.
    Ephraim R; Fraser S; Devereaux J; Stavely R; Feehan J; Eri R; Nurgali K; Apostolopoulos V
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis.
    Saha A; Dreyfuss I; Sarfraz H; Friedman M; Markowitz J
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy.
    Lo YC; Price C; Blenman K; Patil P; Zhang X; Robert ME
    Am J Clin Pathol; 2021 Jul; 156(2):214-228. PubMed ID: 33555016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
    Wang H; Mao L; Zhang T; Zhang L; Wu Y; Guo W; Hu J; Ju H; Ren G
    J Oral Pathol Med; 2019 Sep; 48(8):669-676. PubMed ID: 31132187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects.
    Makaremi S; Asadzadeh Z; Hemmat N; Baghbanzadeh A; Sgambato A; Ghorbaninezhad F; Safarpour H; Argentiero A; Brunetti O; Bernardini R; Silvestris N; Baradaran B
    Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.
    Chen X; Wu W; Wei W; Zou L
    Front Pharmacol; 2022; 13():869488. PubMed ID: 35559250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Checkpoint inhibitor colitis: a new model of inflammatory bowel disease?
    Siakavellas SI; Bamias G
    Curr Opin Gastroenterol; 2018 Nov; 34(6):377-383. PubMed ID: 30157044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.
    Meserve J; Facciorusso A; Holmer AK; Annese V; Sandborn WJ; Singh S
    Aliment Pharmacol Ther; 2021 Feb; 53(3):374-382. PubMed ID: 33314269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery.
    Sipe LM; Chaib M; Korba EB; Jo H; Lovely MC; Counts BR; Tanveer U; Holt JR; Clements JC; John NA; Daria D; Marion TN; Bohm MS; Sekhri R; Pingili AK; Teng B; Carson JA; Hayes DN; Davis MJ; Cook KL; Pierre JF; Makowski L
    Elife; 2022 Jul; 11():. PubMed ID: 35775614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer.
    Kozłowski M; Borzyszkowska D; Cymbaluk-Płoska A
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
    Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
    J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
    Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
    J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.
    Christodoulou MI; Zaravinos A
    Crit Rev Immunol; 2019; 39(5):379-408. PubMed ID: 32422018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
    Dougan M
    Front Immunol; 2017; 8():1547. PubMed ID: 29230210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitors in Oral Cavity Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review.
    Kujan O; van Schaijik B; Farah CS
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.